OxyContin, prescription opioid abuse and economic medicalization - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Medicolegal and Bioethics Année : 2012

OxyContin, prescription opioid abuse and economic medicalization

Résumé

This paper examines the relevance of OxyContin diversion and abuse to the economic medicalization of substance abuse and addiction. Given that medicalization is the general social process of nonmedical problems being transformed into medical problems, economic medicalization occurs where the motivation for the transformation is commercial profitability or, in a corporate context, achieving the objective of shareholder wealth maximization. After considering potential conflicts between medical ethics and business ethics, practical aspects of economic medicalization are detailed by considering the methods used to market OxyContin by Purdue Pharma. Illegal practices are identified and contrasted with legal practices that facilitated economic medicalization. Implications of medicalization research for designing public heath solutions to the epidemic of prescription opioid abuse are discussed.
Fichier principal
Vignette du fichier
MB-32040-oxycontin--medical-ethics-and-economic-medicalization_112212.pdf (785.68 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03680382 , version 1 (27-05-2022)

Identifiants

Citer

Geoffrey Poitras. OxyContin, prescription opioid abuse and economic medicalization. Medicolegal and Bioethics, 2012, pp.31. ⟨10.2147/MB.S32040⟩. ⟨hal-03680382⟩
154 Consultations
72 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More